H-KLVVVGADGV-OH

Ref. 3D-PP48667

Product Information

• Name: H-KLVVVGADGV-OH

Description

Peptide H-KLVVVGADGV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KLVVVGADGV-OH include the following: TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation Y Shen, X Wei, S Jin, Y Wu, W Zhao, Y Xu, L Pan - Asian Journal of , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1818087619311122 Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy W Zhao, J Wu , S Chen, Z Zhou - Pharmacogenomics, 2020 - Future Medicinehttps://www.futuremedicine.com/doi/abs/10.2217/pgs-2019-0184 A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors SN Khleif, SI Abrams, JM Hamilton - Journal of , 1999 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/abstract/1999/03000/A_Phase_I_Vaccine_Trial_with_Peptides_Reflecting.7.aspx Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade P Charoentong , F Finotello , M Angelova , C Mayer - Cell reports, 2017 - cell.comhttps://www.cell.com/cell-reports/pdf/S2211-1247(16)31709-0.pdf Recombinant T cell receptors specific for HLA-A* 02: 01-restricted neoepitopes containing KRAS codon 12 hotspot mutations CM Rive , E Yung, CS Hughes , SD Brown , G Sharma - bioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.06.15.149021.abstract Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers A Toubaji, M Achtar, M Provenzano , VE Herrin - Cancer Immunology , 2008 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0477-6

• Brand: Biosynth